NASDAQ:AMEDAmedisys Stock Price, Forecast & News

Amedisys' stock was trading at $170.47 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AMED shares have increased by 20.0% and is now trading at $204.64. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amedisys.

Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Amedisys.

Amedisys Inc (NASDAQ:AMED) released its quarterly earnings results on Wednesday, May, 6th. The health services provider reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.97 by $0.08. The health services provider earned $491.70 million during the quarter, compared to analyst estimates of $507.45 million. Amedisys had a return on equity of 23.09% and a net margin of 6.43%. The company's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the business earned $1.11 earnings per share. View Amedisys' earnings history.

13 brokerages have issued 12-month price targets for Amedisys' stock. Their forecasts range from $125.00 to $260.00. On average, they anticipate Amedisys' stock price to reach $196.15 in the next twelve months. This suggests that the stock has a possible downside of 4.1%. View analysts' price targets for Amedisys.

News coverage about AMED stock has been trending somewhat negative on Wednesday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Amedisys earned a news impact score of -1.1 on InfoTrie's scale. They also assigned media headlines about the health services provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Amedisys.

Amedisys saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 1,070,000 shares, a drop of 10.8% from the June 15th total of 1,200,000 shares. Based on an average trading volume of 326,500 shares, the short-interest ratio is currently 3.3 days. Approximately 3.4% of the shares of the stock are sold short. View Amedisys' Current Options Chain.

Some companies that are related to Amedisys include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), R1 RCM (RCM), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include Alibaba Group (BABA), NVIDIA (NVDA), Adobe (ADBE), Cisco Systems (CSCO), Netflix (NFLX), CVS Health (CVS), Intel (INTC), Micron Technology (MU), Pfizer (PFE) and Vertex Pharmaceuticals (VRTX).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Riverbridge Partners LLC (2.08%), Envestnet Asset Management Inc. (0.13%), Gradient Investments LLC (0.07%), Louisiana State Employees Retirement System (0.03%), Polianta Ltd (0.02%) and AdvisorShares Investments LLC (0.01%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Linda J Hall, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps. View institutional ownership trends for Amedisys.

AMED stock was sold by a variety of institutional investors in the last quarter, including Gradient Investments LLC. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, and Sharon Brunecz. View insider buying and selling activity for Amedisys.

AMED stock was acquired by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Polianta Ltd, AdvisorShares Investments LLC, Envestnet Asset Management Inc., HBW Advisory Services LLC, Contravisory Investment Management Inc., and Louisiana State Employees Retirement System. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps. View insider buying and selling activity for Amedisys.

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMED stock can currently be purchased for approximately $204.64.

Amedisys has a market capitalization of $6.63 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis. Amedisys employs 21,300 workers across the globe.

The official website for Amedisys is www.amedisys.com.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]